CORRECTED-UPDATE 1-Novo Nordisk hijacks Pfizer with bid for US biotech Metsera

0.00%

+1.28%

+0.22%

+0.19%

+0.31%

Metsera, Inc. MTSR	70.50	0.00%
Pfizer Inc. PFE	26.03	+1.28%
Dow Jones Industrial Average DJI	47954.99	+0.22%
S&P 500 index SPX	6870.40	+0.19%
NASDAQ IXIC	23578.13	+0.31%

Corrects in paragraphs 1 and 2 to say September, not 'last week'

COPENHAGEN, Oct 30 (Reuters) - Denmark's Novo Nordisk NOVOb.CO said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera MTSR.O, after Pfizer PFE.N in September made an offer for the company.

Novo said it had offered $56.50 per share in cash for Metsera, corresponding to an enterprise value of $6 billion, while Pfizer in September said it would pay $47.50 per share in cash, representing $4.9 billion in enterprise value.

Both Novo and Metsera also offered contingent value rights (CVRs) that could add several billion dollars to the purchase price, based on the achievement of clinical and regulatory milestones.

(Reporting by Louise Breusch Rasmussen and Jacob Gronholt-Pedersen, editing by Terje Solsvik)

((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.